EcoDrugPlus

Janus Kinase 1

Ensembl ID : ENSIPUG00000013495
Gene Symbol: JAK1
4 Cross references
165 Possible Orthologues:

Janus Kinase 2a

Ensembl ID : ENSIPUG00000017375
Gene Symbol: JAK2A
3 Cross references
199 Possible Orthologues:

Janus Kinase 2b

Ensembl ID : ENSIPUG00000014352
Gene Symbol: JAK2B
4 Cross references
194 Possible Orthologues:

Kit Proto-Oncogene, Receptor Tyrosine Kinase B

Ensembl ID : ENSIPUG00000004870
Gene Symbol: KITB
4 Cross references
200 Possible Orthologues:

Lyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSIPUG00000002353
Gene Symbol: LYN
3 Cross references
194 Possible Orthologues:

Malt Paracaspase 1

Ensembl ID : ENSIPUG00000015438
Gene Symbol: MALT1
3 Cross references
195 Possible Orthologues:

Mapk Activated Protein Kinase 2a

Ensembl ID : ENSIPUG00000024053
Gene Symbol: MAPKAPK2A
3 Cross references
226 Possible Orthologues:

Mapk Activated Protein Kinase 5

Ensembl ID : ENSIPUG00000016590
Gene Symbol: MAPKAPK5
3 Cross references
179 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 2b

Ensembl ID : ENSIPUG00000014250
Gene Symbol: MKNK2B
3 Cross references
208 Possible Orthologues:

Mcl1 Apoptosis Regulator, Bcl2 Family Member B

Ensembl ID : ENSIPUG00000007039
Gene Symbol: MCL1B
4 Cross references
227 Possible Orthologues:

Mdm2 Proto-Oncogene

Ensembl ID : ENSIPUG00000024445
Gene Symbol: MDM2
3 Cross references
282 Possible Orthologues:

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSIPUG00000013833
Gene Symbol: MET
3 Cross references
206 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).